JP7256580B2 - 結合剤 - Google Patents

結合剤 Download PDF

Info

Publication number
JP7256580B2
JP7256580B2 JP2020530735A JP2020530735A JP7256580B2 JP 7256580 B2 JP7256580 B2 JP 7256580B2 JP 2020530735 A JP2020530735 A JP 2020530735A JP 2020530735 A JP2020530735 A JP 2020530735A JP 7256580 B2 JP7256580 B2 JP 7256580B2
Authority
JP
Japan
Prior art keywords
seq
antigen
antibody
amino acid
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531048A5 (enExample
JP2020531048A (ja
Inventor
ジェイムズ ジョナサン フィンレイ ウィリアム
Original Assignee
ウルトラヒューマン フォー リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1713298.6A external-priority patent/GB201713298D0/en
Priority claimed from GBGB1802595.7A external-priority patent/GB201802595D0/en
Priority claimed from GBGB1808570.4A external-priority patent/GB201808570D0/en
Application filed by ウルトラヒューマン フォー リミティド filed Critical ウルトラヒューマン フォー リミティド
Publication of JP2020531048A publication Critical patent/JP2020531048A/ja
Publication of JP2020531048A5 publication Critical patent/JP2020531048A5/ja
Priority to JP2023049983A priority Critical patent/JP7564274B2/ja
Publication of JP7256580B2 publication Critical patent/JP7256580B2/ja
Application granted granted Critical
Priority to JP2024167571A priority patent/JP7825015B2/ja
Priority to JP2026026439A priority patent/JP2026094226A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2020530735A 2017-08-18 2018-08-17 結合剤 Active JP7256580B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2023049983A JP7564274B2 (ja) 2017-08-18 2023-03-27 結合剤
JP2024167571A JP7825015B2 (ja) 2017-08-18 2024-09-26 結合剤
JP2026026439A JP2026094226A (ja) 2017-08-18 2026-02-20 結合剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1713298.6A GB201713298D0 (en) 2017-08-18 2017-08-18 Binding agents
GB1713298.6 2017-08-18
GB1802595.7 2018-02-16
GBGB1802595.7A GB201802595D0 (en) 2018-02-16 2018-02-16 Binding agents
GBGB1808570.4A GB201808570D0 (en) 2018-05-24 2018-05-24 Binding agents
GB1808570.4 2018-05-24
PCT/GB2018/052347 WO2019034895A1 (en) 2017-08-18 2018-08-17 LIAISON AGENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023049983A Division JP7564274B2 (ja) 2017-08-18 2023-03-27 結合剤

Publications (3)

Publication Number Publication Date
JP2020531048A JP2020531048A (ja) 2020-11-05
JP2020531048A5 JP2020531048A5 (enExample) 2021-09-30
JP7256580B2 true JP7256580B2 (ja) 2023-04-12

Family

ID=63371721

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020530735A Active JP7256580B2 (ja) 2017-08-18 2018-08-17 結合剤
JP2023049983A Active JP7564274B2 (ja) 2017-08-18 2023-03-27 結合剤
JP2024167571A Active JP7825015B2 (ja) 2017-08-18 2024-09-26 結合剤
JP2026026439A Pending JP2026094226A (ja) 2017-08-18 2026-02-20 結合剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2023049983A Active JP7564274B2 (ja) 2017-08-18 2023-03-27 結合剤
JP2024167571A Active JP7825015B2 (ja) 2017-08-18 2024-09-26 結合剤
JP2026026439A Pending JP2026094226A (ja) 2017-08-18 2026-02-20 結合剤

Country Status (14)

Country Link
US (4) US10683350B2 (enExample)
EP (2) EP4435008A2 (enExample)
JP (4) JP7256580B2 (enExample)
KR (1) KR102781208B1 (enExample)
CN (1) CN111212852A (enExample)
AU (2) AU2018316742B2 (enExample)
BR (1) BR112020003306A2 (enExample)
CA (1) CA3072998A1 (enExample)
ES (1) ES2983651T3 (enExample)
IL (1) IL272643A (enExample)
MX (1) MX2020001873A (enExample)
RU (1) RU2020109544A (enExample)
SG (1) SG11202001425TA (enExample)
WO (1) WO2019034895A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019034895A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited LIAISON AGENTS
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
GB201906685D0 (en) 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof
EP3986935A4 (en) 2019-06-19 2023-08-30 Lepu Biopharma Co., Ltd. Anti-cd47 antibodies and uses thereof
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4034171A1 (en) * 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
PH12022550835A1 (en) 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
CN115362003B (zh) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
WO2021142269A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy
WO2021142331A1 (en) * 2020-01-10 2021-07-15 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease
TWI890283B (zh) 2020-02-14 2025-07-11 美商基利科學股份有限公司 結合ccr8之抗體及融合蛋白及其用途
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CN111733162A (zh) * 2020-07-01 2020-10-02 江苏莱森生物科技研究院有限公司 一种经基因修饰的cd47蛋白及其单克隆抗体和应用
WO2022007947A1 (zh) * 2020-07-10 2022-01-13 信达生物制药(苏州)有限公司 抗cd47抗体或其抗原结合片段和dna甲基化转移酶抑制剂的组合及其用途
KR102757518B1 (ko) * 2020-12-07 2025-01-21 (주)이노베이션바이오 Cd47에 특이적인 항체 및 이의 용도
WO2022140659A2 (en) 2020-12-23 2022-06-30 D-10 Therapeutics, Inc. Anti-cd47 antibodies and uses thereof
WO2022190058A1 (en) 2021-03-12 2022-09-15 Dcprime B.V. Methods of vaccination and use of cd47 blockade
CN112794903B (zh) * 2021-04-14 2021-06-25 广州市雷德生物科技有限公司 一种特异性结合IFN-γ的抗体及其应用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4359413A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ， インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
US20250129155A1 (en) * 2021-06-30 2025-04-24 Innobation Bio Co., Ltd. Humanized antibody specific for cd47 and pharmaceutical composition for preventing or treating cd47-related diseases comprising the same
WO2023070353A1 (en) * 2021-10-27 2023-05-04 Adagene Pte. Ltd. Anti-cd47 antibodies and methods of use thereof
EP4423078A1 (en) 2021-10-28 2024-09-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN118488948A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
CA3248911A1 (en) 2022-01-28 2023-08-03 Gilead Sciences, Inc. POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS
IL314395A (en) 2022-01-31 2024-09-01 Centessa Pharmaceuticals Uk Ltd Bispecific anti-CD47 and anti-PD-L1 activatable proteins and their uses
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023191117A1 (ko) * 2022-03-28 2023-10-05 (주)이노베이션바이오 친화도가 성숙된 cd47에 특이적인 인간화 항체
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4511127A1 (en) 2022-04-21 2025-02-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
EP4638436A1 (en) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
JP2026522894A (ja) 2023-06-30 2026-07-09 ギリアード サイエンシーズ， インコーポレイテッド Ｋｒａｓ調節化合物
CN121568935A (zh) 2023-07-26 2026-02-24 吉利德科学公司 Parp7抑制剂
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
EP4774280A1 (en) 2023-09-08 2026-07-15 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20260098049A1 (en) 2024-08-12 2026-04-09 Gilead Sciences, Inc. Kras modulating compounds
US20260130893A1 (en) 2024-10-21 2026-05-14 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2026136515A1 (en) 2024-12-19 2026-06-25 Gilead Sciences, Inc. Parp7 inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170073395A1 (en) 2015-05-18 2017-03-16 Pfizer Inc. Humanized antibodies
WO2017049251A2 (en) 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4637749B2 (ja) * 2003-11-11 2011-02-23 中外製薬株式会社 ヒト化抗ｃｄ４７抗体
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
CN101231382B (zh) 2008-02-26 2010-09-01 上海激光等离子体研究所 用于啁啾脉冲放大的光谱调制整形装置
AU2011252851B2 (en) 2010-05-14 2016-10-06 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to CD47
ME03512B (me) * 2012-02-06 2020-04-20 Inhibrx Inc Cd47 antitijela i postupci za njihovu upotrebu
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
US9221908B2 (en) * 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
WO2016081423A1 (en) * 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
HK1245154A1 (zh) * 2014-12-30 2018-08-24 细胞基因公司 抗cd47抗体及其用途
CA3011097C (en) * 2016-01-11 2022-12-20 Forty Seven, Inc. Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
WO2019034895A1 (en) 2017-08-18 2019-02-21 Ultrahuman Four Limited LIAISON AGENTS
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170073395A1 (en) 2015-05-18 2017-03-16 Pfizer Inc. Humanized antibodies
WO2017049251A2 (en) 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PNAS, 2015, 112(50):15354-15359

Also Published As

Publication number Publication date
US10683350B2 (en) 2020-06-16
JP7564274B2 (ja) 2024-10-08
KR102781208B1 (ko) 2025-03-17
WO2019034895A1 (en) 2019-02-21
CA3072998A1 (en) 2019-02-21
US20220332819A1 (en) 2022-10-20
JP2023073339A (ja) 2023-05-25
AU2018316742B2 (en) 2025-04-10
ES2983651T3 (es) 2024-10-24
JP2026094226A (ja) 2026-06-09
SG11202001425TA (en) 2020-03-30
RU2020109544A (ru) 2021-09-20
KR20200038533A (ko) 2020-04-13
US11370840B2 (en) 2022-06-28
EP4435008A2 (en) 2024-09-25
IL272643A (en) 2020-03-31
JP7825015B2 (ja) 2026-03-05
US20250109202A1 (en) 2025-04-03
JP2020531048A (ja) 2020-11-05
BR112020003306A2 (pt) 2020-08-25
EP3668897A1 (en) 2020-06-24
US20190375840A1 (en) 2019-12-12
EP3668897B1 (en) 2024-06-05
US20200277375A1 (en) 2020-09-03
AU2018316742A1 (en) 2020-03-19
CN111212852A (zh) 2020-05-29
JP2025000787A (ja) 2025-01-07
AU2025204808A1 (en) 2025-07-17
MX2020001873A (es) 2020-10-22

Similar Documents

Publication Publication Date Title
JP7825015B2 (ja) 結合剤
KR102929571B1 (ko) Cd47 결합제
US11851460B2 (en) PD1 binding agents
US12415861B2 (en) Anti C-MET antibodies
JP2025134713A (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
HK40116834A (en) Binding agents
HK40028664A (en) Binding agents
HK40028664B (en) Binding agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210817

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220624

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230327

R150 Certificate of patent or registration of utility model

Ref document number: 7256580

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250